Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC By Ogkologos - August 20, 2025 571 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KRYSTAL-12 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR A toolkit to address disparities in digitally enabled oncology trials September 5, 2025 New Cancer Model Shows Promise in Predicting If Treatment Will Shrink... July 28, 2022 Take with Food: Study Tests Lowering Dose of Prostate Cancer Drug April 23, 2018 Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid... August 12, 2025 Load more HOT NEWS Delayed irAEs Occur in a Small Subset of Patients with Melanoma,... Approval of Elahere Expands Treatment Options for Some Advanced Ovarian Cancers Cancer in My Community: Encouraging Cancer Screening in Estonia How clues from crystals might help us prevent the overtreatment of...
